

Coyne, Terry and Ibiebele, Torukiri and Baade, Peter and McClintock, Christine and Shaw, Jonathan (2009) *Metabolic syndrome and serum carotenoids : findings of a cross-sectional study in Queensland, Australia.* The British Journal of Nutrition: An International Journal of Nutritional Science, 102(11). pp. 1668-1677.

© Copyright 2009 [please consult the authors].

- 1 Article Title:
- 2 Metabolic syndrome and serum carotenoids: findings of a cross-sectional study in Queensland,
- 3 Australia
- 4
- 5 Short running title
- 6 Metabolic syndrome and serum carotenoids
- 7
- 8 <u>Authors:</u>
- 9 Terry Coyne^{1*}, Torukiri I Ibiebele², Peter D Baade³, Christine S. McClintock⁴ and Jonathan E
 10 Shaw⁵
- 11 Affiliations of each author:
- ¹ School of Population Health, University of Queensland, Brisbane, Australia
- ¹³ ² Queensland Institute of Medical Research, Brisbane, Australia
- ¹⁴ ³ Viertel Center for Research in Cancer Control, Cancer Council Queensland, and School of
- 15 Public Health, Queensland University of Technology, Brisbane, Australia
- ⁴ Center for Military & Veterans' Health, University of Queensland, Brisbane, Australia
- ⁵ Baker IDI Heart and Diabetes Institute, Melbourne, Australia
- 18
- 19 * Corresponding author: Dr Terry Coyne, Senior Lecturer (retired) School of Population Health,
- 20 The University of Queensland. P.O. Box 112, Laughlintown PA 15655 USA. Telephone: +1
- 21 (724) 238 2288, Fax: +1 412 242 2840, email: terrycoyne@comcast.net
- 22 <u>Keywords:</u>
- 23 Carotenoids: Metabolic syndrome: Cross-sectional studies
- 24

25 Several components of the metabolic syndrome, particularly diabetes and cardiovascular disease,

- are known to be oxidative stress-related conditions and there is research to suggest that
- 27 antioxidant nutrients may play a protective role in these conditions. Carotenoids are compounds
- derived primarily from plants and several have been shown to be potent antioxidant nutrients.
- 29 The aim of this study was to examine the associations between metabolic syndrome status and
- 30 major serum carotenoids in adult Australians. Data on the presence of the metabolic syndrome,
- based on International Diabetes Federation 2005 criteria, were collected from 1523 adults aged
- 32 25 years and over in six randomly selected urban centers in Queensland, Australia, using a cross-
- 33 sectional study design. Weight, height, BMI, waist circumference, blood pressure, fasting and 2-
- hour blood glucose and lipids were determined, as well as five serum carotenoids. Mean serum

alpha-carotene, beta-carotene and the sum of the five carotenoid concentrations were 35 significantly lower (p<0.05) in persons with the metabolic syndrome (after adjusting for age, 36 sex, education, BMI status, alcohol intake, smoking, physical activity status and vitamin/mineral 37 use) than persons without the syndrome. Alpha, beta and total carotenoids also decreased 38 significantly (p<0.05) with increased number of components of the metabolic syndrome, after 39 adjusting for these confounders. These differences were significant among former smokers and 40 non-smokers, but not in current smokers. Low concentrations of serum alpha-carotene, beta-41 carotene and the sum of five carotenoids appear to be associated with metabolic syndrome status. 42 Additional research, particularly longitudinal studies, may help to determine if these associations 43 are causally related to the metabolic syndrome, or are a result of the pathologies of the 44 syndrome. 45

46

47 <u>Introduction</u>

Although there is no universal definition of the metabolic syndrome, it is generally described as a constellation of pathologies or anthropometric conditions, which include central obesity, glucose intolerance, lipid abnormalities, and hypertension. It is, however, universally accepted that the presence of the metabolic syndrome is associated with increased risk of type 2 diabetes and cardiovascular disease ^(1, 2).

The prevalence of the metabolic syndrome in developed countries varies widely depending upon definitions used and age ranges included, but is estimated to be 24% among adults 20 years and over in the US ⁽³⁾. Given the impending worldwide epidemic of obesity, diabetes and cardiovascular disease, strategies aimed at greater understanding of the pathology of the syndrome, as well as strategies aimed at preventing or treating persons with the syndrome are urgently required.

Both diabetes and cardiovascular disease are known to be oxidative stress-related 59 conditions and some researchers ⁽⁴⁾ suggest that antioxidant nutrients may play a protective role 60 in these conditions. Several cross-sectional surveys ⁽⁵⁻⁷⁾ have found lower levels of serum 61 carotenoids among those with impaired glucose metabolism or type 2 diabetes. Carotenoids are 62 compounds derived primarily from plants and several have been shown to be potent antioxidants 63 ⁽⁸⁾. There is considerable epidemiological evidence that some serum carotenoids may play a 64 protective role against the development of chronic diseases such as atherosclerosis ^(9, 10), stroke 65 ⁽¹¹⁾, hypertension ⁽¹²⁾, certain cancers ^(10, 13), inflammatory diseases ⁽¹⁴⁾ and diabetic retinopathy 66 ⁽¹⁵⁾. The primary carotenoids found in human serum are alpha (α)-carotene, beta (β)-carotene, 67 beta (β)-cryptoxanthin, lutein/zeaxanthin and lycopene ⁽¹⁶⁾ 68

Several studies have found an association between fruit and vegetable intake, or dietary 69 patterns rich in fruit and vegetables, with a lower risk of the metabolic syndrome. ⁽¹⁷⁻²⁰⁾. Other 70 studies, however, have failed to find such associations ⁽²¹⁾ Results of clinical trials testing 71 supplements of these nutrients with chronic diseases, however, have not been promising ⁽²²⁾. 72 Few studies have investigated associations of antioxidant nutrients and the metabolic 73 syndrome. Ford and colleagues ⁽²³⁾ reported lower levels of several carotenoids and vitamins C 74 and E among those with metabolic syndrome present compared with those without the syndrome 75 in the Third National Health and Nutrition Examination Survey. Sugiura et al ⁽²⁴⁾ suggested that 76 several carotenoids may exert a protective effect against the development of the metabolic 77 syndrome, especially among current smokers. Confirming these findings in another population 78 may add strength to these associations. 79

In this study, we investigated the relationships between these five primary serum carotenoids and the metabolic syndrome in a cross-sectional population-based study in Queensland, Australia.

83

84 Subjects and Methods

85 Subjects

The study was conducted in Queensland, Australia between October and December 2000 86 as part of a national study, the Australian Diabetes, Obesity and Lifestyle Study (AusDiab), to 87 determine the prevalence of diabetes and associated cardiovascular risk factors among adults 88 aged 25 years and over. Details of the sampling framework, overall study design, methods and 89 central findings have been published elsewhere ^(25, 26). The study was approved by the 90 International Diabetes Institute and The University of Queensland ethics committees. Six urban 91 92 sites were randomly selected from census collector districts (CDs) in Queensland. The CDs were selected without replacement and with probability proportional to size. Non-institutionalised 93 adults aged 25 years and over residing in private dwellings were included in the survey if they 94 had resided permanently at the address for a minimum of 6 months prior to the survey. Persons 95 with physical or intellectual disabilities that precluded participation in the study were not 96 included. 97

98 Trained interviewers conducted house-to-house interviews and eligible participants were 99 invited to attend a biomedical examination which included collection of blood samples, blood 100 pressure determinations, anthropometric measurements and the administration of standardised 101 questionnaires related to diet as well as socio-demographic, lifestyle and health related 102 characteristics. All respondents gave informed consent to participate in the survey upon arrival at the testing site. A total of 1536 persons (890 females and 646 males) in Queensland
completed the physical examination. Although the overall response rate in the study was low
(70% of eligible adults took part in the initial household survey, and of those, 55% completed
the physical examination), the internal validity and quality control of the data collection were of
high quality ⁽²⁶⁾.

108

109 Methods

Study participants arrived for the examination having fasted for at least 12 hours. Blood pressure measurements were taken using Dinamap sphygmomanometer. Blood was drawn for fasting glucose. Participants not taking hypoglycaemic medication completed an oral glucose tolerance test (OGTT) (two hours after consuming a 75-gram glucose drink). Fasting and twohour (2h) plasma glucose were measured enzymatically (glucose oxidase) on an Olympus AU600 analyser. Participants were also classified as having diabetes if they were receiving treatment for diabetes in the form of tablets or insulin at the time of the study.

Lipids; total cholesterol (chol), high-density lipoprotein cholesterol (HDL), and triglyceride were measured enzymatically on an Olympus AU 600. Low density lipoprotein (LDL) cholesterol was calculated from the equation of Friedwald et al ⁽²⁷⁾: LDL=total cholesterol-[HDL+ (triglyceride/5)]

Blood was drawn for the carotenoid determinations at the time of the 2h OGTT, or 2 121 122 hours after the fasting sample for those who did not have the OGTT. Serum samples were meticulously handled and protected from light at each stage of processing to prevent 123 deterioration and degradation. The serum was pipetted, frozen, packed in dry ice and shipped to 124 the laboratory in Brisbane and were analyzed within three weeks of collection. The five serum 125 carotenoids were assayed simultaneously according to the high performance liquid 126 chromatography (HPLC) procedure described by Talwar et al.⁽²⁸⁾. The intrabatch coefficient of 127 variations by this method were 6.5%, 7.6%, 7.3% 6.9% and 9.0% for α -carotene, β -carotene, β -128 cryptoxanthin, lutein and lycopene respectively and the interbatch (analyzed after stored at -70 C 129 over a period of 8 weeks) CVs were 13%, 9.6%, 8.7%, 8.5 and 11% respectively. 130

The diagnostic criteria for the metabolic syndrome are based on the 2005 International Diabetes Federation (IDF) definition ⁽²⁹⁾. According to the IDF, to be identified as having the metabolic syndrome a person must have *central obesity* (defined as waist circumference \geq 94 cm for Europid men and \geq 80 cm for Europid women, with ethnicity specific values for other groups) plus any two of the following four factors: *raised serum triglyceride level* (\geq 1.7 mmol/L), *reduced serum HDL cholesterol* (<1.03 mmol/L in males and <1.29 mmol/L in females – or 137 specific treatment for these lipid abnormalities), raised blood pressure (systolic blood pressure

 $\geq 130 \text{ mmHg or diastolic} \geq 85 \text{ mmHg}$ - or treatment of previously diagnosed hypertension,

impaired fasting glycemia (fasting plasma glucose ≥5.6 mmol/L or previous diagnosed type 2
 diabetes).

Of those diagnosed with diabetes, 2.5% were classified as having type 1 diabetes and were excluded from the analysis because they do not share common aetiological factors such as obesity, increasing age, nutrition or physical activity with metabolic syndrome. Participants were defined as having Type 1 diabetes if insulin treatment had been started within 2 years of diagnosis and, if they were 40 years of age or older when diagnosed, their current BMI was < 27. Demographic and lifestyle variables were collected using standardised questionnaires.

Height and weight were measured by trained personnel and body mass index (BMI) calculated
as weight (in kilograms)/height (in meters squared). BMI was categorised as: *obese* (BMI ≥30), *overweight* (BMI ≥25 to <30) and *normal weight* (BMI <25). As there were only 18 participants

150 classified as underweight (BMI<18.5), they were grouped with the normal weight group.

Waist circumference was measured half-way between the lower border of the ribs and the
iliac crest on a horizontal plane. Using a steel measuring tape, two measurements were
recorded. If the measurements varied by more than 2 cm, a third measurement was taken. The
mean of the two closest measurements was calculated.

Blood pressure measurement was performed in a seated position after participants had rested for at least 5 minutes, using a Dinamap semiautomatic oscillometric recorder. An appropriate cuff size was used and the arm was supported by a table at heart level. Three readings were taken at 1-minute intervals. The mean of the first two readings was recorded. If the difference between the three readings was greater than 10mmHg, the mean of the two closest measurements was used.

Physical activity beneficial to health was categorised as: *sufficiently active* (greater than 150 minutes "physical activity time" in the previous week), *insufficiently active but not sedentary* (less than 150 minutes "physical activity time" in the previous week), and *sedentary* (no participation in physical activity in the previous week). "Physical activity time" was calculated as the sum of the time spent walking, or performing moderate activity plus double the time spent in vigorous activity to reflect its greater intensity.

Vitamin supplement use during the previous 24 hours was categorised as *yes* for
respondents who indicated that they took any vitamin or mineral supplements on the previous
day and *no* for respondents who indicated they did not.

Criteria used to assess the number of metabolic syndrome components present in a 170 participant using the 2005 International Diabetes Federation⁽²⁹⁾ definition are as follows: 171 Components = 0 -none of the metabolic syndrome components (i.e. abdominal obesity, raised 172 triglyceride, reduced HDL-cholesterol, raised blood pressure, and impaired fasting plasma 173 glucose) are present; Components = any 1 one of the five metabolic syndrome components is 174 present; Components = 2 - any two of the five components are present; Components = 3 any 175 three of the components are present; Components = 4 - any four of the components are present; 176 Components = 5 = all five metabolic syndrome components are present. 177

Participants were asked, "How many serves of vegetables do you usually eat each day? Including fresh, frozen or tinned vegetables (A serve = $\frac{1}{2}$ cup cooked vegetables or 1 cup of salad vegetables)." Usual consumption of fruit was assessed by the question, "How many serves of fruit do you usually eat each day? Including fresh, frozen or tinned fruit (A serve = 1 medium piece or 2 small pieces of fruit or 1 cup of diced pieces of fruit.)." Participants were categorised into three groups according to their responses to both questions; ≤ 1 serve, 2-3 serves, ≥ 4 serves.

184

185 Statistical analyses

Data were analysed using the survey (svy) commands in STATA statistical software version 8 ⁽³⁰⁾. These commands take into account the complex cluster survey design in the calculation of estimates, variance, standard errors and confidence intervals. Age-adjusted means or percentages for selected baseline characteristics were weighted for age and sex to the Oueensland population aged over 25 for the survey year.

Pearson's chi-square statistic was used to assess the relationship between presence or absence of the metabolic syndrome and selected categorical variables. Student's t-test was used to compare differences in means between two groups; analysis of variance was used to assess overall differences in means between serum carotenoids and variables with more than two groups.

Distributions of serum carotenoids were skewed and therefore natural logarithmically transformed to better approximate the normal distribution for regression analyses. Association between log transformed serum carotenoids as dependent variables and metabolic syndrome status were assessed using multiple linear regression analysis. Results are reported as backtransformed geometric means. Analysis was performed for each serum carotenoid separately, and the sum of the five carotenoids, adjusting for the following potential confounders: age, sex, education, BMI, smoking, alcohol intake, physical activity, and vitamin use. We further performed stratified analysis by smoking status to further investigate if the association between
 serum carotenoids and metabolic syndrome is modified by smoking status.

The confounders were included simultaneously into the model. Due to missing values, the sample size is not the same for all analyses.

- 207
- 208 <u>Results</u>

The prevalence of the metabolic syndrome by demographic and health-related 209 characteristics is provided in Table 1. The overall prevalence of the syndrome was 24% and was 210 significantly higher among males than females. As would be expected, significant differences in 211 prevalence of the syndrome were seen with body mass index, waist circumference, systolic and 212 diastolic blood pressure and blood lipids. Significant differences were also evident by age 213 group, smoking status, educational status and income. Income was marginally inversely 214 associated. The prevalence increased with age, and was lower in those with post graduate 215 education. No significant differences were seen by alcohol intake, physical activity levels, 216 217 vitamin usage, or fruit intake. There was actually an inverse relationship between vegetable intake (not fruit) and serum carotenoids. Those who consumed 4 serves or more of vegetable 218 were less likely to have the metabolic syndrome compared to those who consumed 1 serve or 219 less of vegetables. 220

221 (Insert Table 1 about here)

Table 2 provides the adjusted geometric mean of each of the serum carotenoids by metabolic syndrome status. The mean concentrations of serum α -carotene, β -carotene and the sum of the five carotenoids were significantly lower for participants with the metabolic syndrome present compared with those without the syndrome, after adjusting for potential confounding variables including age, sex, educational status, BMI, smoking, alcohol intake, physical activity and vitamin use.

228 (Insert Table 2 about here).

Table 3 shows that concentrations of α -carotene, β -carotene and the sum of the five carotenoids decreased significantly as the number of components of the metabolic syndrome increased after adjusting for potential confounding variables as above. Table 3 also indicates the percentage of participants with none, one, two, three, four or all five of the components.

233 (Insert Table 3 about here)

234 Similarly there was an inverse association between quartiles of individual and total serum 235 carotenoids and metabolic syndrome status and each of its components as shown in Table 4. The strength of these associations was strongest for α -carotene, β -carotene and the sum of the five

237 carotenoids.

238 (Insert Table 4 about here)

Table 5 looks at the effect of smoking status on carotenoid concentrations and metabolic syndrome. No significant differences in serum carotenoid concentrations by metabolic syndrome status were found among 'current smokers'. However, among 'former' and 'never' smokers serum α -carotene and β -carotene were significantly lower among those with metabolic syndrome than those without. In addition, among 'former' smokers serum lycopene was marginally lower in those with metabolic syndrome, while among 'never' smokers total serum carotenoids was marginally lower in those with metabolic syndrome compared to those without.

We also found no significant interaction between smoking status and serum carotenoid concentrations in relation to the metabolic syndrome status. The following are the p values for interaction after adjustment for the confounding variables in relation to: α-carotene (p for interaction=0.25), β-carotene (p for interaction=0.15), β-cryptoxanthin (p for interaction=0.40), lutein/zeaxanthin (p for interaction=0.25), lycopene (p for interaction=0.41), and total serum carotenoid (p for interaction=0.15).

252

(Insert Table 5 about here)

253 <u>Discussion</u>

This study was designed to investigate the association between several serum carotenoids 254 and the metabolic syndrome. The data from the present population study suggest that several 255 serum carotenoids are inversely related to the metabolic syndrome. Our study showed 256 significantly lower concentrations of α -carotene, β -carotene and the sum of the five carotenoids 257 among those with the metabolic syndrome present compared to those without. We also found 258 decreasing concentrations of all the carotenoids tested as the number of the metabolic syndrome 259 components increased. This was significant for α -carotene, β -carotene, β -cryptoxanthin and total 260 carotenoids. These findings are consistent with data reported by Ford et al ⁽²³⁾ from the third 261 National Health and Nutrition Examination Survey (NHANES III). In the NHANES III study, 262 significantly lower concentrations of all the carotenoids, except lycopene, were found among 263 persons with the metabolic syndrome compared with those without, after adjusting for 264 confounding factors similar to those in our study. The NHANES III study ⁽¹⁹⁾ also found 265 decreasing concentrations of all the carotenoids (except lycopene) and total carotenoids with 266 increasing number of metabolic syndrome components. Our study used the criteria for 267 metabolic syndrome as suggested by the International Diabetes Federation⁽³¹⁾, which requires 268

central obesity as the major component. In the NHANESIII study, central obesity is a
component of the syndrome, but it is not a required component. Also we adjusted for BMI in all
of our analyses, whereas the NHANES study did not. This adjustment for BMI may have
attenuated the strength of the association of several carotenoids in our study as compared with
NHANES III.

We did find that all the serum carotenoids decreased as BMI status increased and this was significant for all of the carotenoids. This is consistent with findings of a prospective study by Anderson and colleagues ⁽³²⁾ in which a high BMI status was strongly associated with lower concentrations of total carotenoids.

Since serum carotenoids are considered reliable markers of vegetable and fruit intake, low serum concentrations could conceivably be due to lower intakes. Our previous study ⁽³³⁾ did find statistically significant associations between vegetable and fruit intake and serum levels of α -carotene, β -carotene, β -cryptoxanthin and lutein-zeaxanthin. We also found fewer individuals with the highest vegetable intake with the metabolic syndrome compare with those with the lowest intakes of vegetables. However, we found no association with intake of fruit and the syndrome.

Several studies have investigated fruit and vegetable intake in relation to the metabolic 285 syndrome with mixed results. The NHANES study ⁽¹⁹⁾ reported significantly lower intakes of 286 fruit and vegetables among those with the syndrome present compared to those without the 287 syndrome. To estimate the number of monthly servings of fruit and vegetables, they summed 21 288 items on the NHANES food frequency questionnaire. Esmaillzadeh (18) reported a significant 289 inverse association between fruit and vegetable intake and the metabolic syndrome among 290 Tehrani female teachers. Fruit and vegetable intake was estimated from a semiguantitative food 291 frequency questionnaire. Several studies ^(17, 34) have suggested that a 'healthy' dietary pattern, or 292 one of lower nutritional risk is associated with lower risk of the metabolic syndrome. Another 293 study ⁽²¹⁾ of dietary patterns, however, showed no association with a 'prudent' dietary pattern, 294 typified by a higher intake of vegetables, fruit, fish and poultry, and the metabolic syndrome, but 295 did show a positive association with a 'western' pattern characterised by high intakes of refined 296 grains, processed meat, fried foods and red meat. 297

Although the assessment of fruit and vegetable intake in this study was relatively crude (i.e. how many serves of vegetables do you usually eat in a day?) and therefore may not accurately reflect true fruit and vegetable intake, our findings of vegetable intake does appear to be consistent with those of other studies suggesting a positive relationship between vegetable intake and the risk of the metabolic syndrome. Also our study was conducted from October through December in Queensland, Australia. These months are spring and early summer and as
 most of Queensland is tropical and subtropical the availability of fruit and vegetables is abundant
 year round. Thus the time of year in which the study was conducted would have had little effect
 on results.

Smokers have been found to have significantly lower serum carotenoid concentrations 307 compared with non-smokers ⁽³⁵⁾. Overall, we found significantly lower concentrations of total 308 carotenoids and the individual carotenoids, except lycopene, in smokers compared with non-309 smokers (data not shown). However, in relation to metabolic syndrome status, we found no 310 significant difference in serum carotenoid levels by metabolic syndrome status among current 311 smokers. But among former and never smokers serum alpha-carotene and beta-carotene were 312 relatively lower among those with metabolic syndrome than those without. Serum lycopene was 313 marginally lower for those with metabolic syndrome compared to those without among former 314 smokers, while total serum carotenoids was marginally lower for those with metabolic syndrome 315 compared to those without among never smokers. We also found no significant interaction 316 between smoking status and serum carotenoids in relation to the metabolic syndrome. 317

Our findings were partly similar to that of Sugiura and co-workers ⁽²⁴⁾ who found inverse associations between serum β -carotene among non-smoking adults. Our findings were also similar to those of Hozawa and co-investigators ⁽³⁶⁾, how found an inverse association of total carotenoids with incidence of diabetes and several markers of glucose tolerance only among non- smokers, but no association among current smokers.

There were several limitations in our study. We did not have accurate data on the intake 323 of any of these carotenoids from supplements. Approximately a third of our participants 324 reported taking a vitamin, mineral or herbal supplement in the 24 hours prior to the examination. 325 Although we collected information about the supplements, there was no data base available that 326 could estimate the content of these carotenoids in the supplement. From investigation of a 327 variety of supplements that were on the market at the time, few of them contained any of these 328 carotenoids. Approximately 57% of women in the study were post menopausal, and as might be 329 expected, had higher percentage of women with the syndrome. We did not account for 330 menopause status in our analyses, however, 331

The cross-sectional design of our study does not permit us to draw inferences regarding causality. It is not possible to conclude whether low serum concentrations of carotenoids found in participants with the metabolic syndrome in our study are the result of increased utilisation of these antioxidants due to the oxidative stress effects of the disease or whether the lower concentrations are the result of lower intakes of dietary carotenoids and play a role in thepathogenesis of the syndrome.

Oxidative stress is an imbalance, which produces free radicals that overwhelm the body's 338 antioxidant defences and high levels of oxidative stress are known to deplete the body's reserves 339 of antioxidants. Oxidative stress has been implicated in the pathogenesis of several components 340 of the metabolic syndrome including glucose or insulin abnormalities ⁽⁴⁾, hypertension ⁽³⁷⁾ and 341 obesity ⁽³⁸⁾. Recent studies ⁽³⁹⁾ have reported elevated markers of oxidative stress among subjects 342 with metabolic syndrome compared with those without the syndrome. Thus the oxidative stress 343 nature of the metabolic syndrome may cause greater utilisation of antioxidants resulting in lower 344 concentrations of antioxidants such as carotenoids. 345

Another hypothesis is that lower intakes of antioxidant-rich fruit and vegetables result in 346 lower serum concentrations and thus are involved in the pathogenesis of these conditions. 347 Epidemiologic studies have found lower antioxidant intakes with components of the metabolic 348 syndrome such as diabetes status ⁽⁴⁰⁾. Suzuki and co-workers, ⁽⁷⁾ found a significantly lower 349 odds ratio for high HbA1c among those with the highest intakes of carrots and pumpkin 350 compared with a low intake group. The large EPIC-Norfolk study found that persons with 351 higher intakes of vegetables and fruit have higher serum carotenoid concentrations and lower 352 risk of type 2 diabetes ⁽⁴¹⁾. 353

While numerous observational studies have shown an inverse relationship between 354 antioxidant intakes and serum concentrations and the risk of several of these components, 355 clinical trials providing single or combination antioxidants as supplements have not resulted in 356 any beneficial reduction in these conditions ⁽²²⁾. Further research, particularly longitudinal 357 studies may shed light on whether low levels of carotenoids are causally involved in the 358 development of the syndrome, or if they are a result of these pathologies. Clinical trials based on 359 diets high in carotenoid-rich fruit and vegetables may also provide important insights not only in 360 relation to the prevention of components of the metabolic syndrome, but also in reducing the risk 361 of developing the syndrome itself. 362

Obesity and the other components of the metabolic syndrome are increasing in most countries of the world today and will continue to increase. As populations age, and as overweight and obesity continue to escalate, especially among children, these conditions will become an increasing burden on the health system. Lifestyle interventions have been able to show dramatic reductions in risk of diabetes among those with IGT ^(42, 43). However, strategies for both primary and secondary prevention will be necessary to reduce the burden of obesity,

- 369 diabetes and the metabolic syndrome in future years, in future generations in both developed and
- developing countries.

371 <u>Acknowledgements</u>

This study was supported by the Australian Commonwealth Department of Health and 372 Ageing, Queensland Health, Diabetes Australia, the Australian Kidney Foundation and 373 pharmaceutical companies: Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, Aventis 374 Pharmaceutical, AstraZeneca, Aventis Pharmaceutical, Bristol-Myers Squibb Pharmaceuticals, 375 Eli Lilly (Aust) Pty Ltd, GlaxoSmithKline, Janssen-Cilag (Aust) Pty Ltd, Merck Lipha s.a., 376 Merck Sharp & Dohme (Aust), Novartis Pharmaceutical (Aust) Pty Ltd., Novo Nordisk 377 Pharmaceutical Pty Ltd, Pharmacia and Upjohn Pty Ltd, Pfizer Pty Ltd, Roche Diagnostics, 378 Sanofi Synthelabo (Aust) Pty Ltd., Servier Laboratories (Aust) Pty Ltd. All authors approved 379 the final version of this paper. TC was responsible for the concept and conduct of the study and 380 preparing the manuscript. TII performed the statistical analyses and writing the results section. 381 PDB provided technical assistance on the data analyses and on writing and interpretation. CMcC 382 and JS provided details regarding the study methods and interpretation of findings. None of the 383 authors had any personal or financial interest in the companies that supported the study. No 384 conflict of interest exist. 385

387		References
388 389	1.	Wilson W, D'Agostino R, Parise H, Sullivan L, Meigs J. Metabolic Syndrome as a
390		precursor of cardiovascular disease and type 2 diabetes mellitus.
391		Circulation2005;112:3066-72.
392	2.	Dekker J, Girman C, Rhodes T, Nijpels G, Stehouwer C, Bouter L, et al. Metabolic
393		syndrome and 10-year cardiovascular disease risk in the Hoorn Study.
394		Circulation2005;112(5):666-73.
395	3.	Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults:
396		findings from the Third National Health and Nutrition Examination Survey.
397		JAMA2002;287(3):356-9.
398	4.	Ruhe RC, McDonald RB. Use of antioxidant nutrients in the prevention and treatment of
399		type 2 diabetes. J Am Coll Nutr2001;20(5 Suppl):363S-9S; discussion 81S-83S.
400	5.	Ford ES, Will JC, Bowman BA, Narayan KM. Diabetes mellitus and serum carotenoids:
401		findings from the Third National Health and Nutrition Examination Survey. Am J
402		Epidemiol1999;149(2):168-76.
403	6.	Coyne T, Ibiebele T, Baade P, Dobson A, McClintock C, Dunn S, et al. Diabetes mellitus
404		and serum carotenoids: findings of a population-based study in Queensland, Australia.
405		Am J Clin Nutr2005;82:685-93.
406	7.	Suzuki K, Ito Y, Nakamura S, Ochiai J, Aoki K. Relationship between serum carotenoids
407		and hyperglycemia: a population-based cross-sectional study. J
408		Epidemiol2002;12(5):357-66.
409	8.	Hozawa A, Jacobs DR, Steffes MW, Gross MD, Steffen LM, Lee DH. Relationships of
410		circulating carotenoid concentrations with several markers of inflammation, oxidative
411		stress, and endothelial dysfunction: the Coronary Artery Risk Development in Young
412		Adults (CARDIA)/Young Adult Longitudinal Trends in Antioxidants (YALTA) study.
413		Clin Chem2006;53(3):447-55.
414	9.	D'Odorico A, Martines D, Kiechl S, Egger G, Oberhollenzer F, P B, et al. High plasma
415		levels of alpha- and beta-carotene are associated with a lower risk of atherosclerosis.
416		Results from the Bruneck study. Atherosclerosis2000;153:231-9.
417	10.	Ito Y, Suzuki K, Ishii J, Hishida H, Tamakoshi A, Hamajima N, et al. A population-
418		based follow-up study on mortality from cancer or cardiovascular disease and serum
419		carotenoids, retinol and tocopherols in Japanese inhabitants. Asian Pac J Cancer
420		Prev2006;7(4):533-46.

- 11. Daviglus ML, Orencia AJ, Dyer AR, Liu K, Morris DK, Persky V, et al. Dietary vitamin
 C, beta-carotene and 30-year risk of stroke: results from the Western Electric Study.
 Neuroepidemiology1997;16(2):69-77.
- Hozawa A, Jacobs DR, Jr, , Steffes MW, Gross MD, Steffen LM, Lee DH. <u>Circulating</u>
 <u>carotenoid concentrations and incident hypertension: the Coronary Artery Risk</u>
- 426 <u>Development in Young Adults (CARDIA) study.</u>. J Hypertens2009;27(2):237-42.
- 427 13. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of
 428 tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst2002;94(5):391-8.
- 14. D'Odorico A, Bortolan S, Cardin R, D'Indica R, Martines D, Ferronato A, et al. Reduced
 plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory
 bowel disease. Scand J Gastroenterol2001;36(12):1289-94.
- 432 15. Brazionis L, Rowley K, Itsiopoulos C, O'Dea K. Plasma carotenoids and diabetic
 433 retinopathy. Br J Nutr2008 Jun 13:1-8.
- 434 16. Eitenmiller RR, Landen WO. Vitamin Analysis for the Health and Food Sciences
 435 Illustrated ed. Eitenmiller RR, Landen WO, editors: CRC Press; 1999.
- 436 17. Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. <u>Dietary</u>
 437 patterns, insulin resistance, and prevalence of the metabolic syndrome in women. Am J
 438 Clin Nutr2007;85(3):910-8.
- Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Fruit and
 vegetable intakes, C-reactive protein, and the metabolic syndrome. Am J Clin Nutr
 2006;84(6):1489-97.
- Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant
 concentrations: findings from the Third National Health and Nutrition Examination
 Survey. Diabetes2003 Sep;52(9):2346-52.
- Yoo S, Nicklas T, Baranowski T, Zakeri IF, Yang S-J, Srinivasan SR, et al. Comparison
 of dietary intakes associated with metabolic syndrome risk factors in young adults: the
 Bogalusa Heart Study. Am J Clin Nutr2004;80(4):841-8.
- Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic
 syndrome: the Atherosclerosis Risk in Communities study. Circulation2008;117(6):75461.
- Liu S, Ajani U, Chae C, Hennekens C, Buring JE, Manson JE. Long-term beta-carotene
 supplementation and risk of type2 diabetes mellitus: a randomised controlled trial.
 JAMA1999;282(11):1073-5.

- 454 23. Ford E, Mokdad A, Giles W, Brown D. The metabolic syndrome and antioxidant
 455 concentrations: Findings from the Third National Health and Nutrition Examination
 456 Survey. Diabetes Care2003;52:2346-52.
- 457 24. Sugiura M, Nakamura M, Ogawa K, Ikoma Y, Matsumoto H, Ando F, et al. Associations
 458 of serum carotenoid concentrations with the metabolic syndrome: interaction with
 459 smoking. Br J Nutr2008 Apr 29:1-10.
- Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al.
 The rising prevalence of diabetes and impaired glucose tolerance: the Australian
 Diabetes, Obesity and Lifestyle Study. Diabetes Care2002;25(5):829-34.
- 26. Dunstan DW, Zimmet PZ, Welborn TA, et al. The Australian Diabetes, Obesity and
 Lifestyle Study (AusDiab) -- methods and response rates. Diabetes Res Clin
 Pract2002;57:119-29.
- 466 27. Friedewald WT, Levy R, Fredrickson DS. Estimation of the concentration of low-density
 467 lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin
 468 Chem1972;18:499-502.
- Talwar D, Ha TK, Cooney J, et al. A routine method for the simultaneous measurement
 of retinol, alpha-tocopherol and five carotenoids in human plasma by reverse phase
 HPLC. Clin Chim Acta1998;270:85-100.
- 472 29. Alberti K, Zimmet PZ, Shaw JE. Metabolic syndrome a new world-wide definition. A
 473 Concensus Statement from the International Diabetes Federation. Diabet
 474 Med2006;23(5):469-80.
- 475 30. StataCorp. Stata/SE Statistical Software:Release 8.0 for Windows College Station, TX:
 476 Stata Coorporation. 2003.
- Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A
 Consensus Statement from the International Diabetes Federation. Diabet Med2006
 May;23(5):469-80.
- Andersen LF, Jacobs DR, Jr, , Gross MD, Schreiner PJ, Dale Williams O, Lee DH.
 Longitudinal associations between body mass index and serum carotenoids: the CARDIA
 study Br J Nutr2006;95(2):358-65.
- 483 33. Coyne T, Ibiebele TI, McNaughton S, Rutishauser IH, O'Dea K, Hodge AM, et al.
 484 Evaluation of brief dietary questions to estimate vegetable and fruit consumption using
- 485 serum carotenoids and red-cell folate. Public Health Nutr2005 May;8(3):298-308.

- 486 34. <u>Millen BE, Pencina MJ, Kimokoti RW, Zhu L, Meigs JB, Ordovas JM</u>, et al. <u>Nutritional</u>
 487 risk and the metabolic syndrome in women: opportunities for preventive intervention
 488 from the Framingham Nutrition Study. Am J Clin Nutr2006;84(2):434 41.
- 35. Dietrich M, Block G, Norkus EP, Hudes M, Traber MG, Cross CE, et al. Smoking and
 exposure to environmental tobacco smoke decrease some plasma antioxidants and
 increase -tocopherol in vivo after adjustment for dietary antioxidant intakes. Am JClin
 Nutr2003;77:160 6.
- 493 36. <u>Hozawa A, Jacobs DR, Jr</u>, <u>Steffes MW</u>, <u>Gross MD</u>, <u>Steffen LM</u>, <u>Lee DH</u>. Associations
 494 of serum carotenoid concentrations with the development of diabetes and with insulin
 495 concentration: interaction with smoking: the Coronary Artery Risk Development in
 496 Young Adults (CARDIA) Study. Am J Epidemiol2006;163(10):929-37.
- 497 37. Redon J, Oliva M, Tormos C, Giner V, Chaves J, Iradi A, et al. Antioxidant activities and
 498 oxidative stress byproducts in human hypertension. Hypertension2003;41:1096-101.
- 499 38. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al.
 500 Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin
 501 Invest2004;114(12):1752-61.
- 39. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman M, et al. Metabolic
 syndrome is associated with elevated oxidative stress and dysfunctional dense highdensity lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol
 Metab2004;89(10):4963-71.
- Montonen J, Knekt P, Jarvinen R, Reunanen A. Dietary antioxidant intake and risk of
 type2 diabetes. Diabetes Care2004;27(2):362-6.
- 508 41. Sargent L, Khaw K, Bingham S, Day N, Luben R, Oakes S, et al. Fruit and vegetable
 509 intake and population glycosylated haemoglobin levels: the EPIC-Norfolk Study. Eur J
 510 Clin Nutr2001;55:342-8.
- 511 42. Tuomilehto J, Lindstrom J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by
 512 changes in lifestyle among subjects with impaired glucose tolerance. New Engl J
 513 Med2001;344:1343-50.
- 514 43. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2
 515 diabetes with lifestyle intervention or metformin. New Engl J Med2002;346(6):393-403.
- 516
- 517

Table 1. Age-adjusted means or percentages for selected baseline characteristics of AusDiab participants aged 25 years and over by metabolic syndrome status (N=1523¹)

Selected characteristics (%, mean)		Present		Absent	P value ²
	Ν	Percent or Mean	n	Percent or Mean	
		$(SE)^3$		$(SE)^3$	
Gender (%) ⁴	N	Percent	n	Percent	0.05
Male	195	26.7	451	73.3	
Female	229	21.3	661	78.7	
All persons	424	24.0	1112	76.0	
Age group (yrs) $(\%)^4$					< 0.01
25-34	19	11.0	161	89.0	
35-44	48	14.6	275	85.4	
45-54	114	29.4	270	70.6	
55-64	120	38.4	199	61.7	
65-74	88	38.0	145	62.0	
75+	35	36.2	62	63.8	
Educational status (%)					0.04
Secondary school or less	191	27.5	415	72.5	
Trade certificate, bachelor's degree	214	23.0	598	77.0	
Post-graduate qualification	19	15.8	95	84.2	
Income (%)					0.06
\$800-1500+/week	136	19	465	81	
\$400-799/week	133	24	327	76	
\$0-399/week	147	30	299	70	
Body Mass Index (BMI) (%)					< 0.01
Obese (BMI>30)	208	57.2	149	42.8	
Overweight (BMI ≥ 25 to < 30)	189	28.3	379	71.7	
Normal (BMI<25)	27	3.2	584	96.8	
Smoking status (%)					0.05
Current	59	25.1	147	74.9	
Former smokers	142	29.8	289	70.2	
Never smoked	218	20.8	660	79.2	
Alcohol intake (%)					0.12
None	105	28.0	233	72.0	
\leq 60 std drinks/month	265	22.1	761	77.9	
> 60 std drinks/month	54	27.8	118	72.2	
Physical activity beneficial to health (%)					0.07
Sufficiently active	179	22.0	542	78.0	
Insufficiently active	134	22.2	380	77.8	

111	33.1	185	66.9	
				0.81
265	23.4	705	76.6	
116	22.8	340	77.2	
				0.68
72	25.6	177	74.4	
219	23.4	586	76.6	
123	24.5	329	75.5	
				0.02
168	25.0	426	75.0	
204	24.3	522	75.7	
41	20.1	141	79.9	
	Mean (SE)		Mean (SE)	
420	137.4 (1.9)	1104	121.6 (1.2)	< 0.01
421	73.4 (1.2)	1105	65.8 (1.1)	< 0.01
424	1.15 (0.03)	1112	1.46 (0.01)	< 0.01
424	2.54 (0.14)	1112	1.13 (0.03)	< 0.01
377	3.70 (0.07)	1106	3.37 (0.04)	0.02
424	5.74 (0.08)	1112	5.10 (0.02)	< 0.01
195	106.5 (0.91)	451	91.1 (1.09)	< 0.01
229	97.4 (1.42)	661	78.9 (1.33)	< 0.01
	 265 116 72 219 123 168 204 41 420 421 424 424 377 424 195 	265 23.4 116 22.8 72 25.6 219 23.4 123 24.5 168 25.0 204 24.3 41 20.1 Mean (SE) 420 137.4 (1.9) 421 73.4 (1.2) 424 1.15 (0.03) 424 2.54 (0.14) 377 3.70 (0.07) 424 5.74 (0.08) 195 106.5 (0.91)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	265 23.4 705 76.6 116 22.8 340 77.2 72 25.6 177 74.4 219 23.4 586 76.6 123 24.5 329 75.5 168 25.0 426 75.0 204 24.3 522 75.7 41 20.1 141 79.9 Mean (SE) 420 137.4 (1.9) 1104 421 73.4 (1.2) 1105 65.8 (1.1) 424 1.15 (0.03) 1112 1.46 (0.01) 424 2.54 (0.14) 1112 1.13 (0.03) 377 3.70 (0.07) 1106 3.37 (0.04) 424 5.74 (0.08) 1112 5.10 (0.02)

520 N is not the same because of missing values

521 ²Chi square statistic test of association with adjustment for cluster design; T-test for differences in means for

variables with 2 groups 522

³ Weighted for age and sex to the Queensland population aged over 25 for the survey year; 523

524 SE=Standard Error

⁴ Unadjusted 525

527

528 Table 2. Adjusted¹ geometric mean concentrations of serum carotenoids by metabolic syndrome for adults 25 years

and over who participated in the Queensland AusDiab study, 2000 (N=1523)

530

Serum Carotenoid	Metabolic Sy	vndrome present	Metabolic	P value ²	
(mmol/L)	(n=	=420)	(1		
	Mean ³	95% CI	Mean ³	95% CI	
α-carotene	0.10	0.07-0.15	0.13	0.10-0.18	0.02
β-carotene	0.45	0.33-0.62	0.59	0.47-0.73	0.01
β -cryptoxanthin	0.20	0.16-0.24	0.21	0.18-0.25	0.19
Lutein/zeaxanthin	0.41	0.36-0.46	0.41	0.34-0.50	0.89
Lycopene	0.40	0.34-0.47	0.43	0.39-0.49	0.31
Sum of serum carotenoids	1.82	1.62-2.04	2.02	1.76-2.33	0.04

¹ Multivariable linear regression model adjusting for potential cofounders including: age (25-34, 35-44, 45-54, 55-

532 64, 65-74, 75+); sex (male, female); education (post-graduate qualification, trade-certificate and bachelor degree,

secondary school); BMI (obese, overweight, normal); alcohol intake (>60 drinks per month, <60 drinks per month,

none); smoking (current, former, never); physical activity (sedentary, insufficiently active, sufficiently active); and
vitamin use during 24hrs (yes, no),

² Serum carotenoids were log transformed for regression analyses. Back transformed geometric mean reported in
 table.

538

540

541 Table 3. Mean (SE) age and sex adjusted¹ concentrations of serum carotenoids by metabolic syndrome components

542	among adults 25 years and	over who participated in the	Queensland AusDial	b study, 2000 (N=1523)
-----	---------------------------	------------------------------	--------------------	------------------------

	Number of Metabolic Syndrome components ² present in participants									
	0	1	2	3	4	5				
	n=344	(n=367)	(n=344)	(n=250)	(n=155)	(n=63)				
Proportion of participants with metabolic	22	24	23	17	10	4				
syndrome components (%)										
Serum Carotenoid ⁴ (mmol/L)	Mean (SE) ⁵	Mean (SE)								
α-carotene	0.21 (0.02)	0.18, (0.03)	0.17, (0.02)	0.15, (0.03)	0.12, (0.02)	0.10, (0.01)				
β-carotene	0.83, (0.09)	0.73, (0.10)	0.68, (0.09)	0.60, (0.07)	0.48 (0.06)	0.48 (0.08)				
β-cryptoxanthin	0.29, (0.03)	0.31, (0.04)	0.28, (0.02)	0.26, (0.03)	0.23, (0.02)	0.25, (0.06)				
Lutein/zeaxanthin	0.46, (0.03)	0.44, (0.03)	0.46, (0.03)	0.43, (0.03)	0.46, (0.02)	0.38, (0.03)				
Lycopene	0.62, (0.04)	0.60, (0.04)	0.56, (0.03)	0.49, (0.02)	0.48, (0.03)	0.38, (0.02)				
Total serum carotenoids	2.42, 0.16	2.27, 0.21	2.14, 0.13	1.93, 0.15	1.78, 0.10	1.59, 0.16				

¹Multivariable logistic regression model adjusted for age (25-34, 35-44, 45-54, 55-64, 65-74, 75+); sex (male,

female); education (post-graduate qualification, trade-certificate and bachelor degree, secondary school); BMI

545 (obese, overweight, normal); alcohol intake (>60 drinks per month, <60 drinks per month, none); smoking (current,

546 former, never); physical activity (sedentary, insufficiently active, sufficiently active); and vitamin use (yes, no).

 2 Components = 0 - none of the components of metabolic syndrome are present;

 2 Components =1 - any 1 of the metabolic syndrome components is present

²Components=2 - any 2 of the 5 metabolic syndrome components are present

 2 Components =3 - any 3 of the 5 metabolic syndrome components are present

- 2 Components =4 any 4 of the 5 metabolic syndrome components are present
- 552 2 Components = 5 all 5 metabolic syndrome components are present

³ANOVA used to test for differences in means for variables with more than 2 groups

- ⁴Serum carotenoids not log transformed.
- ⁵SE=Standard Error
- 556
- 557

arotenoids.	Metaboli	ic syndrome	Abdom	inal obesity	High tria	acylglycerol	Low HD	L cholesterol	High fa	asting blood	High b	lood pressure
	(n=424)		(n=424) (n=858) (n=474)			(n=4690		glucose (n=297)		(n=6670		
Serum carotenoids			•									
	OR [†] 95%	CI	OR [†] 95	% Cl	OR [†] 95%	5 CI	OR [†] 95%	S CI	OR [†] 95	% CI	OR [†] 95	5% CI
Alpha carotene (µg/day	/)											
Q1	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref
22	0.76	0.53, 1.08	0.74	0.37, 1.48	0.83	0.59, 1.18	0.65	0.37, 1.13	0.89	0.65, 1.21	0.81	0.57, 1.17
Q3	0.59	0.40, 0.89	0.69	0.55, 0.87	0.53	0.36, 0.78	0.78	0.50, 1.19	0.72	0.47, 1.10	0.56	0.35, 0.91
Q4	0.36	0.21, 0.63	0.47	0.33, 0.65	0.55	0.36, 0.83	0.46	0.24, 0.92	0.54	0.33, 0.90	0.50	0.42, 0.59
P for trend	= 0.005		= <0.01		= 0.011		= 0.06		= 0.011		= <0.01	1
Beta-carotene												
ຊ1	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref
Q2	0.63	0.51, 0.77	0.87	0.33, 2.27	0.70	0.37, 1.33	0.64	0.38, 1.06	0.94	0.47, 1.90	0.47	0.27, 0.80
23	0.56	0.35, 0.89	0.58	0.24, 1.36	0.46	0.31, 0.69	0.60	0.31, 1.40	0.91	0.71-1.17	0.48	0.31, 0.73
Q4	0.36	0.24, 0.55	0.57	0.31, 1.06	0.37	0.21, 0.64	0.39	0.20, 0.76	0.72	0.45, 1.17	0.35	0.23, 0.52
P for trend	=0.003		=0.03		= 0.004		= 0.03		= 0.11		= 0.002	2
Beta-cryptoxanthin												
ຊ1	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref
Q2	1.00	0.62, 1.63	0.77	0.43, 1.37	1.07	0.61-1.89	0.97	0.49, 1.91	1.07	0.75, 1.52	0.93	0.41, 2.09
23	0.68	0.35, 1.32	0.82	0.29-2.29	0.59	0.46, 0.77	0.58	0.37, 0.90	1.09	0.33, 3.59	0.80	0.44, 1.46
24	0.78	0.51, 1.20	0.88	0.47-1.64	0.71	0.46, 1.10	0.59	0.35, 1.01	0.69	0.40, 1.20	0.91	0.43, 1.94
P for trend	=0.07		=0.74		= 0.03		= 0.05		= 0.41		= 0.69	
_utein/zeaxanthin												
Q1	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref
22	1.13	0.55, 2.33	0.91	0.67, 1.25	1.00	0.53, 1.90	0.90	0.45, 1.80	0.95	0.75, 1.20	0.97	0.61, 1.55
23	1.12	0.64, 1.95	1.17	0.72-1.91	1.37	0.85, 2.22	0.55	0.26, 1.18	1.09	0.64-1.88	0.88	0.55, 1.41
24	0.93	0.56, 1.52	0.77	0.36, 1.67	1.19	0.57, 2.48	0.47	0.21, 1.05	0.57	0.33, 1.00	0.95	0.74, 1.23
P for trend	=0.79		=0.72		= 0.37		= 0.04		= 0.13		= 0.53	
_ycopene												
ຊ1	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref

Table 4 (NEW). Odds Ratios (OR[†]) with 95% Confidence Intervals (CI) for Metabolic syndrome and its components according to quartiles of plasma serum carotenoids.

Q2	0.98	0.54, 1.78	1.00	0.73-1.38	1.01	0.47, 2.19	0.93	0.59, 1.44	0.76	0.47, 1.24	1.32	0.96, 1.80
Q3	0.72	0.44, 1.17	0.97	0.63, 1.48	0.76	0.48, 1.22	0.64	0.37, 1.09	0.88	0.54-1.42	1.09	0.80, 1.50
Q4	0.76	0.48, 1.21	0.83	0.53, 1.29	0.75	0.47, 1.19	0.64	0.37, 1.11	1.13	0.86, 1.48	0.98	0.62, 1.57
P for trend	=0.14		= 0.29		=0.07		= 0.06		= 0.20		= 0.54	
Total serum carote	enoids											
Q1	1.00	Ref	1.00	Ref								
Q2	0.63	0.47, 0.85	0.66	0.45, 0.98	1.03	0.66, 1.61	0.63	0.33, 1.18	0.61	0.26, 1.43	0.62	0.35, 1.12
Q3	0.87	0.51, 1.50	0.86	0.66, 1.12	0.88	0.68, 1.12	0.68	0.32, 1.41	0.98	0.73, 1.32	0.57	0.34, 0.94
Q4	0.43	0.23, 0.79	0.60	0.35, 1.02	0.57	0.34, 0.96	0.41	0.20, 1.85	0.56	0.26, 1.22	0.47	0.27, 0.81
P for trend	=0.04		=0.10		= 0.03		= 0.05		= 0.14		= 0.008	}

[†]OR = Odds Ratio Logistic regression adjusted for Adjusted for age (25-34, 35-44, 45-54, 55-64, 65-74, 75+); sex (male, female); education (post-graduate qualification, trade-certificate and bachelor degree, secondary school); alcohol intake (>60drinks per month, <60 drinks per month, none); smoking (current, former, never); physical activity (sedentary, insufficiently active, sufficiently active); vitamin use (yes, no) and BMI (obese, overweight, normal).

	Current smokers (n=183)	P value	Former smokers (Former smokers (n=391)		Never smokers (n=817)			
	Metabolic	Metabolic		Metabolic	Metabolic		Metabolic	Metabolic	P value	
	syndrome absent	syndrome		syndrome	syndrome		syndrome	syndrome		
	present			absent	present		absent	present		
	Mean (95% CI)	Mean (95% CI)		Mean (95% CI)	Mean (95% CI)		Mean (95% CI)	Mean (95% CI)		
Alpha carotene	0.08 (0.07-0.09)	0.07 (0.03-0.14)	0.59	0.14 (0.10-0.21)	0.11 (0.07-0.17)	0.03	0.15 (0.11-0.20)	0.11 (0.08-0.16)	0.04	
Beta-carotene	0.42 (0.36-0.50)	0.38 (0.19-0.76)	0.72	0.63 (0.47-0.84)	0.44 (0.29-68)	0.02	0.63 (0.51-0.78)	0.49 (0.37-0.64)	0.01	
Beta-cryptoxanthin	0.12 (0.10-0.15)	0.11 (0.09-0.15)	0.27	0.22 (0.19-0.25)	0.20 (0.15-0.28)	0.57	0.24 (0.20-0.28)	0.22 (0.18-0.27)	0.40	
Lutein/zeaxanthin	0.33 (0.28-0.40)	0.32 (0.29-0.36)	0.80	0.40 (0.34-0.48)	0.41 (0.34-0.48)	0.87	0.43 (0.35-0.53)	0.41 (0.35-0.48)	0.65	
Lycopene	0.37 (0.27-0.50)	0.39 (0.28-0.53)	0.80	0.48 (0.40-0.58)	0.37 (0.29-0.48)	0.06	0.43 (0.39-0.48)	0.43 (0.39-0.49)	0.97	
Total serum carotenoid	1.47 (1.29-1.67)	1.43 (1.02-2.00)	0.87	2.11 (1.79-2.50)	1.80 (1.45-2.24)	0.10	2.13 (1.85-2.47)	1.92 (1.77-2.10)	0.08	

Table 5. Relation between serum carotenoids and metabolic syndrome by smoking status

Multivariable linear regression adjusting for age (25-34, 35-44, 45-54, 55-64, 65-74, 75+); sex (male, female); education (post-graduate qualification, trade-certificate and bachelor degree, secondary school); alcohol intake (>60 drinks per month, none); physical activity (sedentary, insufficiently active, sufficiently active); vitamin use (yes, no) and BMI (obese, overweight, normal).